SOURCE: StockCall

StockCall

May 18, 2011 09:10 ET

Equity Research on Teva Pharmaceutical Industries Limited and Endo Pharmaceuticals Holdings Inc. -- Drug Manufacturers - Other Look to Acquisitions

JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 18, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) and Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP). Register with us today at www.stockcall.com/ to have free access to these researches.

The never ending battle between branded and generic drug makers always seems to leave companies looking to supplement their product lines when faced with looming patent cliffs. As generic companies steal away market share, large pharmaceutical companies generally look to improve their pipelines through acquisitions. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Manufacturers - Other industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Teva Pharmaceutical Industries Limited and Endo Pharmaceuticals Holdings Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

This happened recently with Teva Pharmaceuticals Industries Limited which agreed to acquire Cephalon Inc. for $6.8 billion recently in order to further its expansion into the branded drug market. In the most recent quarter, Teva saw generic sales weakness in North America weigh on its results, though this was offset by good generics performance throughout Europe. Teva Pharmaceutical Industries Limited research report is accessible for free by registering today at www.stockcall.com/TEVA180511.pdf.

Indeed, patent expirations are a foe of all brand name companies in the sector. Endo Pharmaceuticals Holdings Inc. is another example of the strategy employed by much of the rest of the sector. Endo Pharmaceuticals has resorted to acquisitions to help bolster its pipeline now that the patent cliff for its pain drug Lidoderm approaches. Lidoderm made up around half of the company's revenue in 2010. Endo Pharmaceuticals Holdings Inc. research report is available for free by signing up now at www.stockcall.com/ENDP180511.pdf.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information